Posted by Michael Wonder on 07 Feb 2017
Ablynx submits a marketing authorisation application to the EMA for caplacizumab, its anti-vWF nanobody, for the treatment of aTTP
6 February 2017 - Ablynx is on track to report results of the confirmatory Phase III HERCULES study in the second half of 2017 and these results are expected to support a BLA filing in the United States in 2018.
Ablynx today announced that it has submitted a marketing authorisation application to the EMA for approval of caplacizumab, its first-in-class anti-von Willebrand factor nanobody for the treatment of acquired thrombotic thrombocytopaenic purpura, an ultra-rare, acute, life-threatening blood clotting disorder with a high unmet medical need.
